Follow-up study of expression of Bcl-2, Bax, p53 and ACE in CD34+ cells of peripheral blood and bone marrow in acute leukemia patients in the course of induction chemotherapy


Cite item

Full Text

Abstract

Aim. To determine unbalance in the system of programmed cell death in the cells CD34+ of the bone marrow (BM) and peripheral blood (PB) before and after cytostatic impact in acute leukemia (AL).
Material and methods. Flow cytoflowmetry estimated expression of Bcl-2, Bax, p53 and ACE in the cells CD34+ of BM and PB from 10 AL (4 AML and 6 ALL) patients. PB and BM samples were studied before polychemotherapy (PCT) and in the course of induction treatment: on day +8, +21 (blood only), +36 - 38. Control group consisted of 4 BM donors.
Results. The number of CD34+ cells expressing Bcl-2 in AL patients was 46,5 ± 9,35 % in BM and 39,4 + 10,8 % in PB, in healthy donors - 9 and 32,8 %, respectively. Bax expression in AL patients' cells CD34+ of BM versus this expression in donors was 3 times higher (36,7 ± 8,1 and 14,8%, respectively), of PC - 2 times lower (40,7 ± 6,59 and 75,8%, respectively). Expression of p53 in AL patients was 36,8 ± 9 % in BM and 26 ± 7,4 % in PB, in donors - 28,2 and 65 %, respectively. ACE expression on the cells CD34+ in AL patients in early disease was 62 ± 7,57 % in BM and 48 ± 8,1 % in PB, in donors - 40 and 85 %, respectively. Moreover, there were significant changes in expression of Bcl-2 in BM and Bax, ACE and p53 in PB in the cells CD34+ in AL patients during and after induction PCT.
Conclusion. The above changes evidence for unbalance of pro- and antiapoptosis proteins of regulators in AL patients. PCT changes profile of expression of these proteins, but not to the level of healthy donors.

About the authors

Elena Evgen'evna Khodunova

Email: Hodunova_Lena@mail.ru

Elena Nikolaevna Parovichnikova

Email: elenap@blood.ru

Irina Vladimirovna Gal'tseva

Sergey Mikhaylovich Kulikov

Valentin Grigor'evich Isaev

Valeriy Grigor'evich Savchenko

E E Khodunova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E N Parovichnikova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

I V Galtseva

Hematological Research Center, Moscow

Hematological Research Center, Moscow

S M Kulikov

Hematological Research Center, Moscow

Hematological Research Center, Moscow

V G Isaev

Hematological Research Center, Moscow

Hematological Research Center, Moscow

V G Savchenko

Hematological Research Center, Moscow

Hematological Research Center, Moscow

References

  1. Волкова М. А. (ред.). Клиническая онкогематология: Руководство для врачей. М.: Медицина; 2001.
  2. Савченко В. Г., Паровичникова Е. Н. Лечение острых лейкозов. М. : МЕДпресс-информ; 2004.
  3. Testa U., Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007; 92(1): 81-94.
  4. Li J., Volkov L. et al. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells. Exp. Hematol. 1997; 25: 140-146.
  5. Poeta G. D., Venditti A. et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101(6): 2125-2131.
  6. Marcucci G., Stock W. et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 2005; 23(15): 3404- 3411.
  7. Aksu S., Beyazit Y. et al. Over-expression of angiotensin-converting enzyme (CD143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leukemia and Lymphoma 2006; 47(5): 891-896.
  8. Cavalcanti G. B. Jr., da Cunha Vasconcelos F., Pinto de Faria G. et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B: Clin. Cytom. 2004; 61(1): 1-8.
  9. Antonsson B., Martinou J. C. The Bcl-2 protein family. Exp. Cell Res. 2000; 256(1): 50-57.
  10. Campos L., Rouault J. P., Sabido O. et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091- 3096.
  11. Levine J. L. et al. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
  12. Ladich H. et al. Molecular cell biology. Scientific American books. New Jork, l995.
  13. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-1449.
  14. Kaufmann S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989; 49: 5870-5878.
  15. Van Stijn A., Van Der Pol M. A., Kok А. et al. Differences between the CD34+ and CD34-blast compartments in apoptosis resistance in acute myeloid leukemia. Hematological 2003; 88: 497-508.
  16. Seliger B., Papadileris S., Vogel D. et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur. J. Hematol. 1996; 57: 230-240.
  17. Gump J., Mcgavran L., Wei Q., Hunger S. P. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 2001; 23: 416-425.
  18. Jokubaitis V., Sinka L. et al. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 2008; 111: 4055- 4063.
  19. Inigo S. D., Lopez-Jorge C. E., Gomez-Casares M. T. et al. Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents. Leukemia Res. 2009; 33: 810-816.
  20. Beyazit Y., Aksu S., Haznedaroglu I. C. et al. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J. Natl Med. Assoc. 2007; 99: 57-63.
  21. Herr I., Debatin K. M. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98(9): 2603-2614.
  22. Konopleva M., Tari A. M. et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000; 95: 3929-3938.
  23. Haznedaroglu I. C., Beyazit Y. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. Renin-Angiotensin-Aldosterone Syst. 2010; 11(4): 205-213.
  24. Aksu S., Beyazit Y., Haznedaroglu I. C. et al. Enhanced expression of the local haematopoietic bone marrow renin-angiotensin system in polycythemia Rubra vera. J. Int. Med. Res. 2005; 33: 661-667.
  25. Srinivas G., Nair N. K., Panicker K. R., Pillai M. R. Mutant p53, Bcl-2/Bax ratios and apoptosis in pediatric acute lymphoblastic leukemia. J. Cancer Res. Clin. Oncol. 2000; 126: 62-67.
  26. Hadir A., Nayera H. et al. The expression of Bcl-2 and Bax Proteins and their clinical relevance in ALL and CLL patients. J. Egypt. Natl. Cancer Inst. 2001; 13(1): 35-42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies